# Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

> **NCT01907802** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 8 (actual)

## Conditions studied

- BRAF Gene Mutation
- Hepatic Complication
- Renal Failure
- Solid Neoplasm

## Interventions

- **DRUG:** Dabrafenib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01907802
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-23
- **Primary completion:** 2015-12-16
- **Final completion:** 2015-12-16
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907802, "Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01907802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*